Vera Therapeutics Inc. Class A Common Stock (VERA)
Stock · NASDAQ · Health Care
$27.88as of 10/16/2026
Price chart
Active signals
Resistance level
$33.79
Industry
Biotechnology: Pharmaceutical Preparations
VERA Signal Track Record
How signals performed across all stocks →What VERA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | -0.1% | 49% | September 1, 2026 |
| Bollinger Band Breakout | 23 | +3.6% | 61% | August 25, 2026 |
| Bollinger Band Breakdown | 18 | +2.3% | 56% | October 5, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -3.6% | 43% | July 17, 2026 |
| Any 20-session window (baseline) | -0.2% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluat…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 361
- Website
- veratx.com/
Fundamentals
- 1-day range
- $27.64$29.49
- Market cap
- $2.30B
- P/E (trailing)
- —
- P/E (forward)
- -6.51
- EPS (trailing)
- $-5.86
- Dividend yield
- —
- Beta
- 1.11
- Avg. volume
- 2.17M
52-week range
$23.05$56.05
Next earnings: November 5, 2026 · EPS estimate $-1.61confirmed
Forecasts
14 analyst ratings
Buy 90%
Hold 10%
Sell 0%
1-year price forecast
High
$100
+258.7%
Median
$81.5
+192.3%
Low
$34
+22.0%
Vera Therapeutics Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- VERAVera Therapeutics Inc. Class A Common Stock$27.88▼ 2.42%Market cap $2.30BP/E —$23.05$56.05
- VRDNViridian Therapeutics Inc. Common Stock$19.03▼ 2.71%Market cap $2.32BP/E —$13.18$34.29
- HRMYHarmony Biosciences Holdings Inc. Common Stock$37.95▼ 0.84%Market cap $2.26BP/E 12.36$25.52$43.49
- ZLABZai Lab Limited American Depositary Shares$23.19▼ 1.36%Market cap $2.35BP/E —$12.31$26.6
- SIONSionna Therapeutics Inc. Common Stock$3.89▼ 4.66%Market cap $2.24BP/E —$3.93$54.97
- PVLAPalvella Therapeutics Inc. Common Stock$120.3▼ 5.53%Market cap $2.23BP/E —$68.96$161.38
- MLYSMineralys Therapeutics Inc. Common Stock$20.3▼ 6.19%Market cap $2.23BP/E —$21.46$47.65
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VERA Vera Therapeutics Inc. Class A Common Stock | $2.30B | — | $27.88 | ▼ 2.42% | $23.05$56.05 |
| VRDN Viridian Therapeutics Inc. Common Stock | $2.32B | — | $19.03 | ▼ 2.71% | $13.18$34.29 |
| HRMY Harmony Biosciences Holdings Inc. Common Stock | $2.26B | 12.36 | $37.95 | ▼ 0.84% | $25.52$43.49 |
| ZLAB Zai Lab Limited American Depositary Shares | $2.35B | — | $23.19 | ▼ 1.36% | $12.31$26.6 |
| SION Sionna Therapeutics Inc. Common Stock | $2.24B | — | $3.89 | ▼ 4.66% | $3.93$54.97 |
| PVLA Palvella Therapeutics Inc. Common Stock | $2.23B | — | $120.3 | ▼ 5.53% | $68.96$161.38 |
| MLYS Mineralys Therapeutics Inc. Common Stock | $2.23B | — | $20.3 | ▼ 6.19% | $21.46$47.65 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/2/2026
- Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026Yahoo · 10/2/2026
- Vera Therapeutics To Present Multiple Presentations At American Society Of Nephrology Kidney Week 2026 For Its Final Efficacy Analysis Of ORIGIN 3 Study Of TRUTAKNA In IgA NephropathyBenzinga · 10/2/2026
- Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?Yahoo · 9/24/2026
- 2 ‘Strong Buy’ Stocks Where a Short Squeeze Could Be BrewingYahoo · 9/17/2026
- Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On ThursdayBenzinga · 9/17/2026
- Vera Therapeutics (VERA) Says TRUTAKNA Met All Phase III EndpointsYahoo · 9/17/2026
- Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch NextYahoo · 9/16/2026
Insider Activity
Insider Actions →Acquired
214.7K
Disposed
101.8K
- Fordyce Marshall · September 15, 2026 · Option Exercise18.5K @ $2.9
- Fordyce Marshall · September 15, 2026 · Sale18.5K @ $37
- Young Joseph R · September 11, 2026 · Option Exercise5.0K @ $3.94
- Fordyce Marshall · September 2, 2026 · Option Exercise18.5K @ $2.9
- Fordyce Marshall · September 2, 2026 · Sale18.5K @ $35.12
- Boman Nancy Lee · August 3, 2026 · Grant63.0K
- Boman Nancy Lee · August 3, 2026 · Grant45.0K
- Fordyce Marshall · July 7, 2026 · Option Exercise46.3K @ $2.9
- Fordyce Marshall · July 7, 2026 · Sale2.2K @ $43.59
- Fordyce Marshall · July 7, 2026 · Sale10.5K @ $42.86
- Fordyce Marshall · July 7, 2026 · Sale32.5K @ $42.07
- Fordyce Marshall · July 7, 2026 · Sale1.0K @ $40.78
- Fordyce Marshall · June 23, 2026 · Option Exercise18.5K @ $2.9
- Fordyce Marshall · June 23, 2026 · Sale88 @ $38.43
- Fordyce Marshall · June 23, 2026 · Sale18.4K @ $37.93
Institutional Ownership
March 31, 2026
- Total shares held
- 71.86M
- Total value held
- $2.71B
- Institutional holders
- 222
Top holders this quarter
- Unknown5.89M
- Unknown5.09M
- Unknown4.57M
- Unknown4.11M
- Unknown3.72M
- Unknown3.40M
- Unknown3.36M
- Unknown2.79M
- Unknown2.68M
- Unknown2.68M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Leerink Partners Covers Vera Therapeutics at $34 Target
Leerink Partners has started coverage of Vera Therapeutics, giving it a Market Perform rating and a price target of $34. The target sits near the lower end of the company’s 52‑week range and close to the current support level of $33.79. The new rating may influence how traders view the stock’s short‑term prospects. The RSI of 37 suggests the stock is not overbought or oversold at this time.
Leerink Partners Covers Vera Therapeutics at $34 Target. Leerink Partners has started coverage of Vera Therapeutics, giving it a Market Perform rating and a price target of $34. The target sits near the lower end of the company’s 52‑week range and close to the current support level of $33.79. The new rating may influence how traders view the stock’s short‑term prospects. The RSI of 37 suggests the stock is not overbought or oversold at this time.